These results indicate that RNASE4 level in the plasma of prostate cancer patients is associated with advanced disease status, demonstrating the diagnostic and prognostic value of RNASE4 as an independent biomarker to predict cancer and to determine disease stage prior to biopsy. The gene discussed is RNASE4; the disease is prostate carcinoma.